Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02580552 | Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | PHASE1 | COMPLETED | 66 | — | — | Feb 9, 2016 | Oct 6, 2020 | Nov 23, 2020 | 19 | United States |
| Arm | Type | Description |
|---|---|---|
| Part A, MF | EXPERIMENTAL | Intratumoral Injection of cobomarsen |
| Part B, MF | EXPERIMENTAL | Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy |
| Part C, MF | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part D, CLL | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part E, DLBCL, activated B-cell (ABC) subtype | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Part F, ATLL | EXPERIMENTAL | Subcutaneous or intravenous administration of cobomarsen as monotherapy |
| Name | Type | Description |
|---|---|---|
| Cobomarsen | DRUG | - |
Inclusion Criteria: * Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III (excluding visceral or nodal involvement), and must be refractory to or intolerant of established therapies for their condition * Part D only: Patients diagnosed with CLL who are intolerant to, o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Soligenix, Inc. | SNGX | 1 | PHASE3 | Hypericin |
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | — | Undisclosed |